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The main reasons for the inefficiency of standard glioblastoma (GBM) therapy are the occurrence of chemoresistance and the
invasion of GBM cells into surrounding brain tissues. New therapeutic approaches obstructing these processes may provide
substantial survival improvements. The purpose of this study was to assess the potential of lipophilic antioxidant coenzyme Q10
(CoQ10) as a scavenger of reactive oxygen species (ROS) to increase sensitivity to temozolomide (TMZ) and suppress glioma
cell invasion. To that end, we used a previously established TMZ-resistant RC6 rat glioma cell line, characterized by increased
production of ROS, altered antioxidative capacity, and high invasion potential. CoQ10 in combination with TMZ exerted a
synergistic antiproliferative effect. These results were confirmed in a 3D model of microfluidic devices showing that the CoQ10
and TMZ combination is more cytotoxic to RC6 cells than TMZ monotherapy. In addition, cotreatment with TMZ increased
expression of mitochondrial antioxidant enzymes in RC6 cells. The anti-invasive potential of the combined treatment was
shown by gelatin degradation, Matrigel invasion, and 3D spheroid invasion assays as well as in animal models. Inhibition of
MMP9 gene expression as well as decreased N-cadherin and vimentin protein expression implied that CoQ10 can suppress
invasiveness and the epithelial to mesenchymal transition in RC6 cells. Therefore, our data provide evidences in favor of CoQ10
supplementation to standard GBM treatment due to its potential to inhibit GBM invasion through modulation of the
antioxidant capacity.
1. Introduction
Glioblastoma (GBM) is the most common primary malig-
nant tumor with an astrocytic lineage [1]. Treatment options
for this type of brain tumor remain limited. The current
first-line standard of care is maximal surgical resection and
radiotherapy with concomitant and adjuvant chemotherapy
with temozolomide (TMZ), a DNA alkylating agent that
can cross the blood-brain barrier [2]. Unfortunately, the
recurrence rate is high (~ 90%) and the median overall
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survival of GBM patients is 15 to 18 months, with less than
10% 5-year survival rate [3]. To a vast extent, the reason lies
in the high level of intratumor heterogeneity and complex
tumor microenvironment resulting in aggressive invasive-
ness and resistance to radio- and chemotherapy.
Invasion of glioma cells into brain parenchyma is a com-
plex process that includes changes in cell-cell adhesion,
remodeling of the extracellular matrix (ECM), and cell
migration [4]. Glioma cells have a characteristic migratory
pattern along blood vessel membranes or myelinated nerve
fibers of the white matter [5]. Cell-cell adhesion is compro-
mised during epithelial-mesenchymal transition (EMT), the
process that enables transit of polarized epithelial cells to
invasive mesenchymal phenotype. This transition is accom-
panied by a decreased expression level of epithelial genes
(e.g., E-cadherin, ZO-1, and occludin) and increased expres-
sion level of mesenchymal genes (e.g., N-cadherin, vimentin,
and fibronectin) [6]. Different types of proteases are involved
in ECM degradation and remodeling, including members of
the matrix metalloproteinase (MMP) family, their inhibitors
(tissue inhibitors of metalloproteinases (TIMP)), urokinase-
type plasminogen activator (uPA) and its receptor, and
cathepsin B. Increased expression of these proteases posi-
tively correlates with invasion potential and glioma grade
[7, 8]. Malignant gliomas also express a variety of integrin
receptors which interact with different components of ECM
(e.g., tenascin, laminin, and vitronectin) [9]. This interaction
induces cytoskeletal rearrangement and promotes migration.
In addition, there are complex bidirectional associations
between development of drug resistance and EMT in various
types of cancer [10, 11]. Thus, glioma cells resistant to
bis-chloroethyl nitrosourea (BCNU), also known as carmus-
tine, showed a significant decrease in E-cadherin expression,
increase in vimentin expression and phenotypic changes
consistent with EMT, spindle-shaped morphology, and
enhanced pseudopodia formation [12].
Resistance to DNA-damaging agents, including TMZ, is
usually followed by altered reactive oxygen species (ROS) pro-
duction inmitochondria [13, 14].Mitochondria are themajor
ROS producers due to leakage of electrons from electron
transport chains which leads to partial reduction of oxygen
and formation of superoxide [15]. Superoxide is dismutated
to H2O2 by manganese superoxide dismutase (MnSOD) in
the mitochondrial matrix or copper/zinc SOD (CuZnSOD)
in the cytosol. Decomposition of H2O2 to oxygen and water
is mediated by catalase (CAT) and glutathione peroxidase
(GPx) with a help of glutathione reductase (GR) [16].
Our RC6 rat glioma model previously established from a
C6 cell line is characterized by resistance to BCNU and TMZ
(the only two drugs which have been approved so far by FDA
for high-grade glioma treatment), lower proliferation rate,
and increased invasion potential in vitro and in vivo [17,
18]. The main mechanism implicated in this resistant and
highly invasive phenotype is the alteration of oxidative bal-
ance with an elevated level of ROS production and an
increased expression of genes involved in redox regulation
(MnSOD, GPx, and iNOS) [18].
Herein, we wanted to explore the influence of coenzyme
Q10 (CoQ10), a lipid-soluble antioxidant involved in the
mitochondrial electron transport chain, on RC6 cell-
resistant and invasive phenotypes. In addition to direct anti-
oxidant scavenging, CoQ10 regenerates vitamin E and ascor-
bate from their oxidized state [19]. CoQ10 supplementation
has significant impact on the expression of many genes
involved in cell signaling, metabolism, and transport [20].
Various diseases associated with CoQ10 deficiency can ben-
efit from CoQ10 supplementation including cardiovascular
and neurodegenerative diseases and cancer [21]. Recently,
Frontiñán-Rubio et al. showed that CoQ10 treatment
enhances DNA damage induced by radiation and potenti-
ates TMZ cytotoxicity in human glioblastoma cell lines
[22]. In addition, some mathematical works have hypothe-
sized a synergistic effect of antioxidants in combination
with chemotherapeutics [23].
Therefore, our first goal was to investigate the potential of
antioxidant CoQ10 in sensitization of RC6 cells to TMZ,
in vitro and in microfluidic devices. Next, we explored the
single and combined effects of CoQ10 and TMZ on ROS pro-
duction and expression of enzymatic components involved
in redox regulation. We further tested the ability of single
and combined CoQ10 and TMZ treatments to suppress the
invasive capacity of RC6 cells in vitro and in vivo and finally
examined the mechanism underlying inhibition of RC6 inva-
sive phenotype.
2. Materials and Methods
2.1. Drugs and Agents. Temozolomide (TMZ) was purchased
from Schering-Plough, Labo NV, Heist-op-den-Berg, Bel-
gium. Coenzyme Q10 (CoQ10) (Kaneka Corporation) was
kindly provided by Dr. Mario Durán-Prado from the Faculty
of Medicine, University of Castilla-La Mancha, Spain. TMZ
was diluted in dimethyl sulfoxide (DMSO) and 100mM ali-
quots were stored at 4°C. New 2mM CoQ10 aliquots in
DMSO were prepared for each treatment.
2.2. Cells and Culture Conditions. RC6 cells were selected
from C6 cells by continuous exposure to stepwise increasing
concentrations of BCNU for nine months [18]. Cells were
maintained in DMEM medium supplemented with 10%
FBS, 2mM L-glutamine, 4.5 g/l glucose, 5000U/ml penicillin,
and 5mg/ml streptomycin solution at 37°C in humidified 5%
CO2 atmosphere. Passaging was performed in 72 h intervals
using 0.25% trypsin/EDTA, and cells were seeded into fresh
medium in a concentration of 8000 cells/cm2.
2.3. Cell Viability Analysis In Vitro and Median-Effect
Analysis. Sulforhodamine B (SRB) assay (Sigma-Aldrich,
Darmstadt, Germany) was used to assess the combined effect
of CoQ10 and TMZ on RC6 cell growth. 2000 cells/well were
seeded in 96-well flat-bottom plates and incubated for 24h at
37°C. Cells were then treated for 72h with different concen-
trations of TMZ (10, 25, 50, 100, and 250μM) combined with
different concentrations of CoQ10 (5, 10, and 25μM). After-
wards, cells were fixed in 50% trichloracetic acid for 1 h at
4°C, rinsed in tap water, and stained with 0.4% SRB in 1%
acetic acid for 30min at room temperature. The cells were
then rinsed three times in 1% acetic acid to remove the
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unbound stain. The protein-bound SRB stain was extracted
with a 10mM Tris base. Absorbance was measured at
540nm using an automated microplate reader (LKB 5060-
006 Microplate Reader, LKB, Vienna, Austria). Half-
maximal inhibitory concentration (IC50) values were defined
as the concentration of the drug that inhibited cell growth by
50% andwas calculated by nonlinear regression analysis using
GraphPad Prism 6 software (La Jolla, CA, USA).
The median-effect analyses are based on the median-
effect principle established by Chou and Talalay [24] which
was used to calculate the combination index (CI) value for
the interaction between TMZ and CoQ10. The analyses were
carried out using CalcuSyn software (Biosoft, Cambridge,
UK). We used at least three data points for each single drug
in each designed experiment. The nonconstant ratio combi-
nation was chosen to determine the effect of both drugs in
combination. CI < 1 indicates synergism, CI = 1 indicates
an additive effect, and CI > 1 indicates antagonism.
2.4. Cell Viability Analysis in Microfluidic Devices. The
microfluidic devices used in our experiments were designed
by the Group of Applied Mechanics and Bioengineering
(AMB), Aragón Institute of Engineering Research (I3A),
University of Zaragoza, Spain, and fabricated by BEONCHIP
(Spain). The microfluidic chips were previously validated in
drug toxicity analysis [24]. The microfluidic device com-
prises of a central microchamber and two lateral microchan-
nels. Due to its specific design, a hydrogel can be confined in
the central microchamber without invading the lateral
microchannels. In this way, a 3D system was developed with
the tumor cells being embedded in a collagen hydrogel, mim-
icking extracellular matrix, in the central microchamber. The
lateral microchannels remained hydrogel-free, mimicking
blood vessels, and were used for the delivery of medium with
nutrients, oxygen, or drugs as required.
For the preparation of three-dimensional cell cultures in
collagen hydrogels, all reagents and microdevices were
placed on ice. 4 × 106 RC6 cells were resuspended in 50μl
of medium. Cell suspension was then mixed with 50μl of
hydrogel (35.7μl of collagen type I (Corning®, New York,
USA); 0.89μl 1M NaOH; 10μl 5x DMEM; 3.4μl dH2O),
and 10μl of this mixture was injected in the central micro-
chamber. Polymerization of the hydrogel was carried out
for 15min in the incubator, and then, lateral microchannels
were perfused with medium to allow oxygen and nutrient
diffusion. After 2 h, this medium was removed and a fresh
one with 10μM CoQ10, 250μM TMZ, or their combina-
tion was perfused through the lateral microchannels. Drops
of medium were left at each lateral microchannel inlet to
prevent evaporation. Cell viability was examined after 72 h
with calcein (CAM) (1 : 1000; Thermo Fisher Scientific,
MA, USA)/propidium iodide (PI) (4μg/ml; Sigma-Aldrich,
Darmstadt, Germany) staining. Images of microdevices
were taken using a Nikon Eclipse Ti microscope (Nikon
Instruments Inc., Tokyo, Japan) equipped with a C1 modu-
lar confocal microscope system, at 2x magnification. The
results were analyzed using Fiji® software and represented
as PI fluorescence intensity across the microdevice. At least
three independent experiments were performed.
2.5. ROS Production in Microfluidic Devices. Preparation of
three-dimensional cell cultures in microfluidic devices was
performed as described in Cell viability analysis in microflui-
dic device subsection. The medium with 10μM CoQ10 was
perfused through the lateral microchannels. ROS production
was examined using 25μM CellROX® Orange (Thermo
Fisher Scientific, MA, USA) that was also perfused through
the lateral microchannels after 2 h and 4h. Images of micro-
devices were taken using a Nikon Eclipse Ti microscope
equipped with a C1 modular confocal microscope system, at
10x magnification. The results were analyzed using Fiji® soft-
ware and represented as fluorescence intensity of oxidized
CellROX® Orange across the segment of the microdevice.
At least three independent experiments were performed.
2.6. RNA Extraction, Reverse Transcription, and Real-Time
Quantitative PCR. RC6 cells were treated with 10μM
CoQ10, 250μM TMZ, or their combination for 24 h. Total
RNA was isolated from these samples and control RC6 cells
without treatment using TRIzol® reagent (Invitrogen Life
Technologies, MA, USA) according to the manufacturer’s
instructions. RNA was quantified by spectrophotometry, and
quality was determined by agarose gel electrophoresis. RT
reactions were performed using 2μg of total RNA, with a
high-capacity cDNA reverse transcription kit (Applied Bio-
systems,CA,USA), following themanufacturer’s instructions.
Real-time quantitative PCR (qRT-PCR) was performed
in order to determine MnSOD [25], CuZnSOD, CAT, GR
[26], iNOS [27], MMP9 [17], and β-actin [28] gene expres-
sion levels. Prepared 100ng cDNAs were amplified using
Maxima SYBR Green/ROX qPCR Master Mix (Thermo
Fisher Scientific, MA, USA), according to the recommenda-
tions of the manufacturer, in a QuantStudio 3 Real-Time
PCR System (Thermo Fisher Scientific, MA, USA). Thermo-
cycler conditions comprised an initial step at 50°C for 5min,
followed by a step at 95°C for 10min and a subsequent 2-step
PCR program at 95°C for 15 s and 60°C for 60 s for 40 cycles.
The accumulation of PCR products was detected in real time;
the results were analyzed using the QuantStudio™ Design
and Analysis Software 1.3.1. and presented as 2−ΔCt [29], Δ
Ct being the difference between Ct values of specific genes
and β-actin as endogenous control.
2.7. Protein Isolation and Western Blot Analysis. RC6 cells
were treated with 10μM CoQ10, 250μM TMZ, or their
combination for 24 h. Proteins were isolated from these sam-
ples and control RC6 cells without treatment in RIPA buffer
containing complete protease and phosphatase inhibitor
cocktails (Roche, Mannheim, Germany). Total protein con-
centrations were measured with Micro BCA™ Protein Assay
Kit (Thermo Fisher Scientific, MA, USA), using bovine
serum albumin as standard.
Equal amounts of proteins (35μg) were separated by 8%
or 12% SDS-PAGE and transferred onto PVDF membranes
(GE Healthcare, Buckinghamshire, UK). The membranes
were blocked with 3% bovine serum albumin in blotto base
buffer (0.1% Tween 20, 20mM Tris-HCl pH7.6, 137mM
NaCl) for 1 h at room temperature and incubated overnight
at 4°C in the same buffer containing rabbit polyclonal
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antibodies specific to CAT (1 : 2000; ab16731; Abcam, UK),
GR (1 : 2000; ab16801; Abcam, UK), CuZnSOD (1 : 2000;
ab13533; Abcam, UK), MnSOD (1 : 5000; ab13498; Abcam,
UK), iNOS (1 : 1000; MABN527; Darmstadt, Germany), or
GAPDH (1 : 5000; G9545; Darmstadt, Germany) and mouse
polyclonal antibodies specific to vimentin (1 : 1000; M0725;
Dako, Denmark) or N-cadherin (1 : 5000; 610921; BD Biosci-
ences, USA). After washing for five times with blotto base
buffer, horseradish peroxidase- (HRP-) conjugated bovine
anti-rabbit IgG secondary antibody (1 : 5000; ab6721; Abcam,
UK) or rabbit anti-mouse IgG secondary antibody (1 : 3000;
P0260; Dako, Denmark) was applied in the same buffer for
1 h at room temperature. Immunoreactive bands were
detected on medical X-ray blue film (Carestream Health Inc.,
NY, USA) by the enhanced chemiluminescence (ECL) detec-
tion system (Santa Cruz Biotechnology, TX, USA) according
to the manufacturer’s instructions. Densitometric quantifica-
tion of immunoreactive bands was performed using Image-
Quant (GE Healthcare) image analysis software (ver. 5.2)
and expressed as relative values normalized to GAPDH as
internal control.
2.8. Gelatin Degradation Assay. RC6 cells were plated on top
of glass coverslips (20000 cells per coverslip) coated with
Alexa Fluor 488-labeled gelatin (Gelatin from Pig Skin, Ore-
gon Green® 488 Conjugate, Life Technologies, MA, USA) in
6-well plates. The cells were treated with 10μM CoQ10,
250μM TMZ, or their combination. Corresponding control
was used. After 24 h, cells were fixed with 4% paraformalde-
hyde (PFA) and costained with Hoechst 33342 (1 : 1000;
Sigma-Aldrich, Darmstadt, Germany) and ActinRed 555
(1 : 500; Invitrogen Life Technologies, MA, USA). The cover-
slips were analyzed at a 20x magnification under a Zeiss
Axiovert inverted fluorescent microscope (Carl Zeiss Foun-
dation, Heidenheim, Germany). The volume of the dark area
caused by degradation of gelatin was measured in ImageJ
software (v.1.48, Microsoft, WA, USA) and normalized in
relation to the volume of the cell. At least 100 cells were ana-
lyzed per experiment.
2.9. Matrigel Invasion Assay. In Matrigel invasion assay,
Transwell inserts (membrane pore size, 8μm; diameter,
6.4mm; BD Biosciences Discovery Labware, USA) were
placed in 24-well plates. 70000 RC6 cells were seeded in
serum-free medium in the upper chambers covered with a
layer of Matrigel Basement Membrane Matrix (5mg/ml,
BD Biosciences) and treated 24 h with 10μM CoQ10,
250μM TMZ, or their combination. Corresponding
untreated cells were used as a positive control. The lower
chambers were filled with DMEM medium supplemented
with 10% FBS as chemoattractant. A negative control with
serum-free medium in the lower chamber was also included
in the experiment. After the incubation, cells that invaded
through the Matrigel and its underlying membrane were
fixed in 4% PFA and stained with Hoechst 33342 (1 : 1000).
Cells (their nuclei) present at the lower surfaces of the mem-
branes were counted under a Zeiss Axiovert inverted fluores-
cent microscope, at 10x magnification. The average number
of cells in 30 independent fields per membrane was analyzed
using ImageJ software. At least three independent experi-
ments were performed.
2.10. 3D Tumor Spheroid Invasion Assay. RC6 spheroids
were generated using the hanging drop method with methyl-
cellulose, as previously described [17]. For 3D invasion assay,
25μl of spheroids was embedded in hydrogel mixture
(17.85μl collagen type I; 0.45μl 1M NaOH; 5μl 5x DMEM;
1.7μl dH2O), placed on top of 50μl of hydrogel, and treated
with 10μM CoQ10, 250μM TMZ, their combination, or
50μM GM6001 (Selleckchem, TX, USA). Control without
treatment was included. After 24 h, spheroids were stained
with CAM (1 : 1000) and PI (1 : 500) in order to visualize
spheroids and test viability. Images of spheroids were taken
using a Nikon Eclipse Ti microscope equipped with a C1
modular confocal microscope system, at 20x magnification.
The size of spheroids was analyzed using Fiji® software. At
least 10 spheroids were analyzed per experiment.
2.11. Animal Studies. Three-month-old male Wistar rats
were used for in vivo experiments. All animal procedures
were in compliance with Directive (2010/63/EU) on the pro-
tection of animals used for experimental and other scientific
purposes and were approved by the Ethical Committee for
the Use of Laboratory Animals of the Institute for Biological
Research “Siniša Stanković,”University of Belgrade. The ani-
mals were housed under standard conditions (23 ± 2°C,
60%–70% relative humidity, 12 h light and dark cycles, and
free access to water and food).
The animal model was established as previously
described by Stojković et al. [17]. Briefly, animals were anes-
thetized with Nembutal (Serva, Heidelberg, Germany) at
50mg/kg, administered intraperitoneally (i.p.). 105 CFSE-
labeled RC6 cells (Invitrogen Life Technologies, MA, USA)
in 5μl suspension were injected in brain parenchyma (pri-
mary motor cortex) using a Hamilton syringe. TMZ and
CoQ10 were dissolved in DMSO and further diluted in
0.9% NaCl for subsequent i.p. administration. Animals were
randomly divided into 4 groups; each group consisted of 5
animals: the control group, the group that received 10mg/kg
CoQ10 (starting the 5th day after cell inoculation, 2 times a
week for three weeks), the group that received 4mg/kg
TMZ (starting the 12th day after cell inoculation, 5 days con-
secutively), and the CoQ10 + TMZ group that received the
combination regimen. After 25 days, animals were sacrificed
and brains were removed and fixed in 4% PFA and cryopro-
tected in 30% sucrose in PBS. The brains were cut in coro-
nal sections and stained with Hoechst 33342 (1 : 1000) for
nuclei visualization. Images of coronal sections were taken
using a Zeiss Axiovert inverted fluorescent microscope, at
5x magnification.
2.12. Statistical Analysis. Statistical analyses were performed
by GraphPad Prism 6 software (La Jolla, CA, USA). Data
normality was estimated using Shapiro-Wilk’s test. The data
obtained by SRB assay were analyzed by two-way ANOVA,
using Dunnett’s multiple comparisons test. Invasion assays,
qRT-PCR, and Western blot experiments were analyzed by
Student’s t-test. Gelatin degradation data did not have a
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normal distribution, so the Wilcoxon matched-pair signed
rank test was carried out. The observed differences were con-
sidered statistically significant if p < 0 05.
3. Results
3.1. CoQ10-Sensitized RC6 Cells to TMZ In Vitro and in
Microfluidic Devices. First, we assessed the inhibitory effect
of combined CoQ10 and TMZ treatments on RC6 cell
growth after 72 h using the SRB assay. The application of all
CoQ10 concentrations (5μM, 10μM, and 25μM) decreased
the IC50 values for TMZ. More prominent effects were
obtained with 10μM and 25μM CoQ10 concentrations,
showing 2.4-fold and 3.3-fold decreases in IC50 for TMZ,
respectively (Figure 1). The obtained results were analyzed
using a synergism/antagonism CalcuSyn software tool. Con-
centrations of 10μM CoQ10 and 250μM TMZ whose com-
bination index (CI) was 0.427 were used in single and
combined treatments in the following experiments. Never-
theless, all tested combinations showed synergistic effects
having CI < 1 (data not shown).
Then, microfluidic devices were employed to study the
efficacy of the proposed treatments in conditions that reflect
more accurately the complex tumor microenvironment. 4 ×
107 RC6 cells/ml were embedded in a collagen hydrogel
and injected in the central microchamber of microfluidic
device. Lateral microchannels were perfused with growth
medium, or medium supplemented with 10μM CoQ10,
250μM TMZ, or their combination. After 72 h, cells were
stained with CAM and PI (Figure 2(a)). Treatment with
CoQ10 did not change the intensity of PI fluorescence imply-
ing that CoQ10 did not induce cell death. TMZ treatment led
to an increase of the PI fluorescence intensity in an area adja-
cent to the lateral microchannels confirming its cytotoxicity.
Combined treatment produced more intense increase of PI
fluorescence in a much wider area adjacent to the lateral
microchannels compared to single TMZ treatment suggest-
ing synergistic interaction between two drugs (Figure 2(b)).
3.2. CoQ10, Alone and in Combination with TMZ,Modulated
Oxidative Balance and Antioxidant Enzyme Expression in
RC6 Cells. Microfluidic devices were also used to assess the
effect of CoQ10 on ROS production in RC6 cells. Again, 4
× 107 RC6 cells/ml were embedded in collagen hydrogel
and injected in the central microchamber. Lateral micro-
channels were perfused with growth medium or medium
supplemented with 10μM CoQ10. After 2 h and 4h, cells
were stained with CellROX® Orange (Figure 3(a)). Results
are presented as intensity of fluorescence that corresponds
to oxidized reagent CellROX® Orange (ROS indicator).
Treatment with CoQ10 led to decrease in ROS production
at both tested time points (Figure 3(b)). The effect did not
fade from 2h to 4 h indicating that ROS decrease after
CoQ10 application is not transient.
To test if any components of the antioxidative system
could be modulated by CoQ10, we analyzed the expression
of MnSOD, CuZnSOD, CAT, GR, and iNOS by qRT-PCR
and Western blot in RC6 cells treated for 24h with 10μM
CoQ10 and 250μM TMZ, alone and in combination
(Figure 4). Treatments with TMZ alone and in combination
with CoQ10 led to a significant increase of MnSOD mRNA
expression in RC6 cells of 3.2-fold (p ≤ 0 001) and 2.2-fold
(p ≤ 0 01), respectively. This trend was also detected at a pro-
tein level, where all three treatments led to a similar increase,
around 2-fold (p ≤ 0 001), in protein expression (Figure 4(a)).
The combination also increased mRNA expression and pro-
tein expression of CuZnSOD by 1.4-fold (p ≤ 0 001) and
1.3-fold (p ≤ 0 01), respectively (Figure 4(b)). Increased
CATmRNA expression by the combined treatment (1.5-fold,
p ≤ 0 001) was followed by a similar increase in CAT protein
expression (1.3-fold, p ≤ 0 05) (Figure 4(c)). Additionally,
cotreatment with CoQ10 and TMZ significantly increased
mRNA and protein expression of GR, 1.2-fold (p ≤ 0 05)
and 1.8-fold (p ≤ 0 001), respectively (Figure 4(d)). Likewise,
treatment with either CoQ10 or the combination increased
iNOS mRNA expression 2.5-fold (p ≤ 0 05) or 3-fold
(p ≤ 0 01), respectively, while iNOS protein expression
remained unchanged (Figure 4(e)).
3.3. Single and Combined CoQ10 and TMZ Treatments
Decreased the Invasiveness of RC6 Cells and Spheroids. Then,
we tested the capacity of CoQ10 and TMZ to suppress gelatin
degradation that was previously identified as an important
feature of RC6 aggressive phenotype (Figure 5(a)). We found
that the ability of RC6 cells to degrade gelatin was signifi-
cantly inhibited (p ≤ 0 001) after single 10μM CoQ10 and
250μM TMZ treatments (2-fold and 4-fold, respectively),
while their combination caused an 8-fold decrease in gelatin
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Figure 1: Combined effect of CoQ10 and TMZ on RC6 cell growth.
Cell viability was determined using SRB assay 72 h after treatment.
IC50 values for each CoQ10 concentration are included next to
the graph. The average ±SEM was obtained from four
independent experiments. Statistical significance: 5μM CoQ10 to
0 μM CoQ10, p < 0 05 ($) and p < 0 001 ($$$); 10 μM CoQ10 to
0 μM CoQ10, p < 0 01 (##) and p < 0 001 (###); 25 μM CoQ10 to
0 μM CoQ10, p < 0 01 (∗∗) and p < 0 001 (∗∗∗).
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degradation compared to the untreated control (p ≤ 0 001)
(Figure 5(b)).
Additionally, invasion assay was used to investigate the
anti-invasive potential of 10μM CoQ10 and 250μM TMZ
as well as their combination (Figure 6). We found that
CoQ10 and its combination with TMZ significantly
suppressed the invasion of RC6 cells through Matrigel by
50% and 80% (p ≤ 0 01), respectively, when compared to
untreated cells.
Finally, a 3D invasion assay was performed to evaluate
the anti-invasive properties of the abovementioned treat-
ments (Figure 7). Our results showed that CoQ10
RC6 control CoQ10
TMZ TMZ + CoQ10
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Figure 2: Cell death induction in a microfluidic device. (a) Representative images of microfluidic devices with RC6 cells embedded in collagen
hydrogel in the central microchamber. Growth medium and medium supplemented with 10 μMCoQ10, 250 μMTMZ, or their combination
were perfused through both lateral microchannels, and after 72 h, cell viability was assessed by CAM (green) and PI (red) staining. The
position of the pillars is defined with white dashed lines. Scale bar = 500 μm; (b) the graph displays the PI fluorescence intensity along the
delimited region in control, single, and combined CoQ10 and TMZ treatments.
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Figure 3: ROS production in a microfluidic device. (a) Representative images of microfluidic devices with RC6 cells embedded in collagen
hydrogel in the central microchamber. Free medium or medium with 10 μM CoQ10 was perfused through both lateral microchannels;
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control and CoQ10 treatment.
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Figure 4: Effects of single and combined CoQ10 and TMZ treatments on gene and protein expression of antioxidant enzymes. Real-time
qRT-PCR and Western blot analysis were used to assess (a) MnSOD, (b) CuZnSOD, (c) CAT, (d) GR, and (e) iNOS mRNA and protein
expression after 24 h treatment with 10 μM CoQ10, 250μM TMZ, or their combination. The mRNA expression and protein expression
were normalized to the internal control, β-actin and GAPDH, respectively. Relative protein expression is accompanied by representative
immunoblots. The average ±SEM was obtained from at least three independent experiments. Statistical significance is presented as
p < 0 05 (∗), p < 0 01 (∗∗), and p < 0 001 (∗∗∗).
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significantly decreases the invasion of RC6 spheroids in
collagen hydrogel by 33% (p ≤ 0 01), while the TMZ effect
was weaker leading to a decrease of 20% (p ≤ 0 05). The
most pronounced effect was observed in the combination
treatment, which significantly inhibited invasion of RC6
spheroids by 60% (p ≤ 0 001). Furthermore, the effects of
CoQ10, TMZ, and their combination on RC6 invasion abil-
ity were compared to the effect of GM6001, a broad-
spectrum matrix metalloproteinase inhibitor. Treatment
with 50μM GM6001 significantly decreased the invasion
of RC6 spheroids by 38% (p ≤ 0 01), which was comparable
to CoQ10 treatment.
RC6 control
TMZ
CoQ10
CoQ10 + TMZ
(a)
5
4
3
G
el
at
in
-d
eg
ra
de
d 
su
rfa
ce
(v
s. 
ce
ll 
ar
ea
)
2
1
0
RC
6 
co
nt
ro
l
C
oQ
10
TM
Z
C
oQ
10
 +
 T
M
Z
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
(b)
Figure 5: Suppression of gelatin degradation by RC6 cells. (a) Representative images of RC6 cells plated on Oregon Green® 488 Conjugate
Gelatin (green) and treated with 10μMCoQ10, 250μM TMZ, or their combination. After 24 h, cells were stained with Hoechst 33342 (blue)
and ActinRed 555 (red); dark areas represent spots of degraded gelatin. Scale bar = 200 μm. (b) Histogram shows a degraded surface of
Oregon Green® 488 Conjugate Gelatin per total area of cells in control and treatments. The average ±SEM obtained from three
independent experiments is presented. Statistical significance is presented as p < 0 001 (∗∗∗).
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Figure 6: Anti-invasive potential of CoQ10, TMZ, and their combination. Representative images of RC6 cells that invaded through Matrigel
to the opposite side of the membrane obtained after 24 h treatment. Nuclei of RC6 cells were stained with Hoechst 33342 (blue). “RC6 control
+” is positive control (with FBS as chemoattractant) and “RC6 control –” is negative control (without chemoattractant). Scale bar = 50 μm.
Histogram shows the number of cells that invaded through Matrigel and passed the membrane. The average ±SEM obtained from three
independent experiments is presented. Statistical significance is presented as p < 0 01 (∗∗).
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Further, we searched for the mechanism responsible for
the anti-invasive potential of CoQ10 and TMZ combination.
To that end, we analyzed MMP9 mRNA expression by qRT-
PCR as well as N-cadherin and vimentin protein expression
by Western blot (Figure 8). CoQ10, TMZ, and their combi-
nation significantly decreased the expression of MMP9
mRNA in RC6 cells by 1.7-fold, 1.9-fold, and 6-fold, respec-
tively (p ≤ 0 001, Figure 8(a)) indicating a strong potentiation
of the studied effect when CoQ10 and TMZ were applied in
combination. We found that CoQ10, TMZ, and their combi-
nation induced a similar reduction in N-cadherin expression
2-fold (p ≤ 0 01), 1.9-fold (p ≤ 0 05), and 2.3-fold (p ≤ 0 01),
respectively (Figure 8(b)), while CoQ10 and the combination
led to a significant decrease of vimentin expression in RC6
cells by 1.6-fold (p ≤ 0 001) and 1.4-fold (p ≤ 0 01), respec-
tively (Figure 8(c)).
3.4. Anti-Invasive Effects of Single and Combined CoQ10 and
TMZ Treatments of RC6 Orthotopic Allograft. Motivated by
the results obtained in vitro, our further research was aimed
at confirming these results in vivo. Previously, we had devel-
oped an orthotopic allograft by inoculation of CFSE fluores-
cently labeled RC6 cells in the Wistar rat brains. To study the
effects of CoQ10, TMZ, and their combination, we divided
animals into 4 groups: the control group, group treated with
10mg/kg CoQ10 (i.p., twice a week for three weeks), the
group treated with 4mg/kg TMZ (i.p., 5 times consecutively
during the second week), and the group treated with the
combination of CoQ10 and TMZ (i.p., scheduled as single
treatments). Coronal brain sections showed that RC6 cells
in the control group migrated into distant ipsilateral brain
structures and were found as far as in the ipsilateral olfactory
bulb. Cells were present in dispersed clusters representing
one of the main features of their infiltration pattern. Treat-
ment with CoQ10 exhibited an anti-invasive effect as seen
on corresponding coronal brain sections. RC6 cells were
found in clusters near the injection site and at the outermost
edge of the ipsilateral olfactory bulb. Fluorescently labeled
RC6 cells on coronal brain sections of animals treated with
TMZ were detected in distant brain regions where they
followed an already established invasion pattern. The most
noticeable anti-invasive effect was observed in animals
treated with CoQ10 and TMZ combination, where the
majority of RC6 cells stayed near the injection site (Figure 9).
4. Discussion
Despite the growing knowledge of the GBM development
and progression, treatment advances and options are still
poor. Results of current treatments for newly diagnosed
and recurrent GBM are disappointing, and there is an
urgent need for finding new modalities in chemotherapy.
Several studies were undertaken to increase TMZ efficacy
in GBM. Thus, various substances including interferon-β
[30], ribonucleotide reductase inhibitors [31], and valproic
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Figure 7: Effects of CoQ10, TMZ, and their combination on RC6 spheroid invasion. Representative images of RC6 spheroids embedded in
collagen hydrogel and treated with 10 μM CoQ10, 250μM TMZ, their combination, or 50μM GM6001. After 24 h, spheroids were stained
with CAM (green) and PI (red). Scale bar = 200μm. Graph displays size of spheroids as a measure of their invasion potential. The average
±SEM obtained from three independent experiments is presented. Statistical significance is presented as p < 0 05 (∗), p < 0 01 (∗∗), and
p < 0 001 (∗∗∗).
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acid [32] increased the sensitivity of GBM to TMZ through
different mechanisms.
In this study, we used a TMZ-resistant RC6 cell line in
order to test the potential of CoQ10, as an antioxidant, to
enhance TMZ efficacy. CoQ10 drew our interest since it is a
natural compound also synthesized by human cells [33]. In
addition, it is a lipophilic compound able to cross the
blood-brain barrier [34], which makes it suitable for glioma
treatment. Due to its redox modulatory potential, CoQ10
may influence invasiveness and resistance, the key features
associated with GBM pathology. Indeed, we showed that
CoQ10 increased the sensitivity of RC6 cells to TMZ that is
in accordance with a recent study in which CoQ10 increased
radio- and TMZ sensitivity in human GBM cell lines, without
affecting normal astrocytes [22]. However, 2D cell cultures
are not able to portray the complex cellular interactions
and specific environmental settings occurring in tumors,
which is often the reason for drug failure in later research
stages. Therefore, we used a 3D microfluidic model to closely
mimic microenvironmental conditions and their effect on
drug response [35]. Within the microfluidic device, RC6 cells
embedded in collagen hydrogel in the central microchamber
represented a “tumor slice” with specific microenvironmen-
tal conditions at different distances from surrogate blood ves-
sels (the lateral microchannels). For this one and all
subsequent experiments, we used 10 μMCoQ10, the concen-
tration detected in human plasma after oral ingestion [36].
The results obtained using the 3D model confirmed that
CoQ10 and TMZ combination was more effective in induc-
ing RC6 cytotoxicity than TMZ treatment alone. Combined
treatment created wider and more intense areas of cell death
around the lateral microchannels probably due to different
spatial distributions.
Oxidative stress and ROS have an important role in
EMT through regulation of signaling pathways (e.g., NF-κB
and TGF-β) required for MMP activation, ECM degrada-
tion, and loss of cell-cell junctions, as well as reversible or
irreversible oxidative modification of the cytoskeleton pro-
tein components [37]. Increased ROS levels can activate
NF-κB signaling and thus induce transcription of vimentin
and MMPs as well as EMT-related morphological changes
[38, 39]. Therefore, ROS reduction may diminish EMT pro-
gression implying antioxidants as beneficial agents for the
inhibition of cancer invasion and metastasis.
Exogenously administered CoQ10 predominantly incor-
porates into mitochondrial membranes [40]. A recent study
showed that incubation of human GBM cells with CoQ10
reduced mitochondrial O2
- production and H2O2 levels
[22]. Our results in a 3Dmicrofluidic device model confirmed
that CoQ10 alone reduced ROS production in rat RC6 cells
causing a significant increase in MnSOD and CAT protein
expression. Combined treatment with CoQ10 and TMZ led
to a significant increase in MnSOD, CuZnSOD, CAT, and
GR protein expression. Although CoQ10 alone and cotreat-
ment with TMZ prominently increased iNOSmRNA expres-
sion, this change was not reflected at the protein level. In this
way, CoQ10 exerted its antioxidant activity in RC6 cells by
direct scavenging of ROS (e.g., O2
-), the transformation of
O2
- to H2O2, and its subsequent degradation to H2O as a
result of an increase in mitochondrial antioxidant capacity.
According to Tsai et al., overexpression of catalase leads
to the decreased production of H2O2 and consequent inhibi-
tion of lung cancer cell migration and invasion [41]. Other
evidences have established a positive correlation between
H2O2 content and MMP2 activity in MCF-7 breast cancer
cells also showing that CoQ10 application decreases H2O2
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Figure 8: Effects of single and combined CoQ10 and TMZ treatments on MMP9 gene expression and protein expression of mesenchymal
phenotype markers. Real-time qRT-PCR analysis was used to assess (a) MMP9 mRNA expression while Western blot analysis was used to
determine (b) N-cadherin and (c) vimentin protein expression after 24 h treatment with 10 μM CoQ10, 250μM TMZ, or their
combination. The mRNA expression and protein expression were normalized to the internal control, β-actin and GAPDH, respectively.
Relative protein expression is accompanied by representative immunoblots. The average ±SEM was obtained from at least three
independent experiments. Statistical significance is presented as p < 0 05 (∗), p < 0 01 (∗∗), and p < 0 001 (∗∗∗).
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production leading to the inhibition of MMP2 activity [42].
Likewise, CoQ10 caused a decrease in O2
- level in mitochon-
dria, inhibited MMP2 and MMP9 activity, and reduced
tumor volume and the number of metastasis in mouse lung
carcinoma [43]. We demonstrated that combined treatment
with CoQ10 and TMZmore efficiently decreased gelatin deg-
radation and Matrigel and spheroid invasion in comparison
with single treatments. Moreover, galardin (GM6001), a
potent broad-spectrum MMP inhibitor, exhibited reduction
of RC6 spheroid invasion at the level equivalent to single
CoQ10 treatment.
Significant inhibition ofMMP9 gene expression, a domi-
nant form of gelatinase expressed in RC6 cells, together with
significant inhibition of N-cadherin and vimentin, mesen-
chymal phenotype markers, implied both MMPs and EMT
blockage as a possible anti-invasive mechanism of combined
CoQ10 and TMZ treatment. Other potent antioxidants, such
as resveratrol and curcumin, increased the expression of
epithelial phenotype marker E-cadherin and reduced the
expression of mesenchymal phenotype markers, vimentin
and fibronectin, thus suppressing TGF-β1-induced EMT in
lung and hepatoma cell lines [44, 45]. Our in vitro results
were confirmed in RC6 orthotopic allograft, where CoQ10
and TMZ cotreatment efficiently interrupted the distinctive
infiltration pattern of RC6 cells towards the ipsilateral
olfactory bulb. Other authors also showed that CoQ10 could
be valuable in combination with clinically approved chemo-
therapeutics, i.e., CoQ10 combined with tamoxifen signifi-
cantly reduced the tumor weight and volume in rat
mammary carcinoma [46].
Figure 9: In vivo study of RC6 invasion in orthotopic allograft. Representative images of Wistar rat brain coronal sections from the RC6
control group, CoQ10 group, TMZ group, and CoQ10 + TMZgroup. Inoculated cells were stained with fluorescent dye CFSE (green), and
nuclei were counterstained with Hoechst 33342 (blue). Scale bar = 200 μm. Enlarged images in the corners of RC6 control and CoQ10
group images display RC6 cells at the edge of and in the ipsilateral olfactory bulb.
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5. Conclusions
In summary, we have demonstrated that CoQ10 sensitizes
RC6 cells to TMZ and enhances TMZ-induced cell death in
a 3D model. CoQ10 and TMZ applied in combination
inhibited invasion of RC6 cells in vitro and in vivo, by modi-
fying mitochondrial antioxidant capacity and expression of
MMP9 and EMTmarkers. Significant advances in GBM ther-
apy have not yet been achieved despite invested efforts.
Recent clinical studies of erlotinib and cilengitide, as promis-
ing targeted therapeutics, in combination with standard GBM
treatments have failed in phase II or III clinical trials [47, 48].
Our study highlights the benefit of CoQ10 supplementation
in GBM therapy and provides a solid basis for further pre-
clinical and clinical research of CoQ10 and TMZ combina-
tion. Therefore, CoQ10 which is widely used in human
diet and different pathologies as a supplement could be con-
sidered as a valuable addition to standard GBM treatment.
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